The Low Hematopoietic Ability of BAIC's Own Brand Breeds High Risk
Recently, Daimler, a joint-venture partner of BAIC, has taken a series of actions such as wanting to increase its stake in Beijing Benz and developing cooperating with Geely, which has aroused great attention to the future development of BAIC. In this context, the further increase of centrifugal force of the joint venture brand also reflects a grim reality faced by BAIC, that is, the continuous weakening of its own sector in recent years and relying on the joint venture “blood transfusion”. According to statistics, BAIC revenue reached 174.63 billion yuan in 2019, with a year-on-year increase of 15%, and its gross profit was 37.487 billion yuan, with a year-on-year increase of 1.30%. However, in breaking down the four major sectors, the joint venture business of Beijing Benz stands out in terms of revenue and gross profit. Its revenue accounts for 88.8% of the company's total revenue, and its gross profit is even higher than the company's overall total. Data show that from 2016 to 2019, the sales volume of BAIC's owned brands are 457,000, 236,000, 156,000 and 167,000 respectively, with gross profit margins of -2.8%, -15.4%, -21.3% and -24.3%, respectively. The gross profit loss of BAIC’s own brands in 2019 continued to increase, expanding from -3.516 billion yuan in 2018 to -4.728 billion yuan in 2019, including 1.04 billion yuan of government subsidies for BAIC New Energy in 2019. Due to the low profitability of its own brand, BAIC has become an inefficient asset in the joint venture.